Vol 14, No 5 (2018)
Guidelines / Expert consensus
Published online: 2019-02-15
Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018
Oncol Clin Pract 2018;14(5):272-277.
Abstract
New recommendations for HER2 status (receptor or gene) testing in breast cancer were published following
long-term analysis of clinical effectiveness of molecularly targeted treatment based on predictive factor of
HER2 status. The new protocols were developed to eliminate equivocal cases, and the new procedure leads to
final statement as HER2 positive or HER2 negative. Current testing algorythms are presented.
Keywords: HER2breast cancerrecommendations
References
- www.pathologyoutlines.com (26.09.2018).
- Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. JCO. 2018; 36: 1–20.
- Olszewski W, Chmielik E, Kordek R. Sutek. Pol J Pathol. 2015; 66(4; Suppl 1): 30–35.
- Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, et al. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am J Clin Pathol. 2012; 137(5): 691–698.
- Hanna W, Barnes P, Berendt R, et al. Testing for HER2 in breast cancer: current pathology challenges faced in Canada. Curr Oncol. 2012; 19(6): 315–323.